Perspectives and progress in development of breast cancer chemopreventive drugs.
Kelloff
G J
GJ
Division of Cancer Prevention and Control, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Boone
C W
CW
Crowell
J A
JA
Nayfield
S G
SG
Hawk
E T
ET
Steele
V E
VE
Lubet
R A
RA
Sigman
C C
CC
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D001943:Breast Neoplasms / Q000517:prevention & control*; D003687:Dehydroepiandrosterone / Q000627:therapeutic use; D004965:Estrogen Antagonists / Q000627:therapeutic use; D005260:Female; D017313:Fenretinide / Q000627:therapeutic use; D006801:Humans; D012307:Risk Factors; D013629:Tamoxifen / Q000627:therapeutic use
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D004965:Estrogen Antagonists; D013629:Tamoxifen; D017313:Fenretinide; D003687:Dehydroepiandrosterone